Berlin, Germany - November 22, 2006 – New research has found that a new medication, tegaserod, is effective in treating nearly all symptoms associated with chronic constipation (CC), a common disorder of the gastrointestinal tract that affects approximately 15% of the Western population at any one time. Tegaserod is currently the only drug aside from laxatives found to be effective at treating such a wide variety of symptoms. This research is published in The American Journal of Gastroenterology.
No specific cause for chronic abdominal discomfort and bowel-movement irregularity has ever been identified. Several approaches for treating CC, such as increased fiber intake and lifestyle changes are frequently used, however, evidence for their effectiveness in improving the multiple symptoms of CC is limited.
“Chronic constipation is a complex medical disorder and several bodily mechanisms are involved in its development,” says Stefan Müller-Lissner, M.D., lead author of the study. “The positive results we have found from tegaserod treatment in relieving this array of symptoms could potentially benefit millions.”
The long-term safety, efficacy and tolerability of tegaserod have been proven. Patients show no serious side-effects from long-term usage and maximal improvements were observed after approximately 6 months of further treatment and were sustained thereafter.
This study is published in the current issue of The American Journal of Gastroenterology. Media wishing to receive a PDF of this article please contact Medicalnews@bos.blackwellpublishing.net
Stefan Müller-Lissner, M.D., is a professor of Internal Medicine/Gastroenterology at Humboldt University, Berlin. He is head of the Department of Internal Medicine, vice medical director of Park-Klinik Weissensee, a teaching hospital of Humboldt University and the author of more than 300 scientific papers and articles. He can be reached for questions at mueli@park-klinik.com
About the Journal
The American Journal of Gastroenterology meets the day-to-day demands of clinical practice. Aimed at practicing clinicians, the journal's articles deal directly with the disorders seen most often in patients. The journal brings a broad-based, interdisciplinary approach to the study of gastroenterology, including articles reporting on current observations, research results, methods of treatment, drugs, epidemiology, and other topics relevant to clinical gastroenterology. For more information, please visit www.blackwell-synergy.com/loi/ajg
Blackwell Publishing is the world’s leading society publisher, partnering with 665 academic and professional societies. Blackwell publishes over 800 journals and, to date, has published more than 6,000 books, across a wide range of academic, medical, and professional subjects. Please visit www.blackwellpublishing.com for more information.